TDF + LNG Vaginal Ring
Alternative Name: Tenofovir Disoproxil Fumarate (TDF) + Levonorgestrel Vaginal Ring
Product Details
User: Female
Hormonal: Yes
Delivery Method: Vaginal Ring
Duration Type: Short-acting
Duration: 30 days
Regimen: - leave in place for 30 days
- leave in place for 30 days
Active Pharmaceutical Ingredient (API): - levonorgestrel
- tenofivir disoproxil fumarate (TDF)
- levonorgestrel
- tenofivir disoproxil fumarate (TDF)
Inactive material: polyurethane
Multipurpose Preventive Technology (MPT): Yes
Status Details
Developer: Albert Einstein College of Medicine, NIAID, Northwestern University
Project Phase: Pre-Clinical and Clinical Development
Development Stage: Phase I
Active Development: Unknown
Status Details: - A clinical trial conducted in 2014 in New York evaluated the ring in 60 women over 14 days. The trial assessed the ring's safety and measured how much of the drug is released and the properties of the ring after use.
- Another phase I trial began in 2017 to evaluate the safety of the ring over 84 days. The trial was not completed.
- A clinical trial conducted in 2014 in New York evaluated the ring in 60 women over 14 days. The trial assessed the ring's safety and measured how much of the drug is released and the properties of the ring after use.
- Another phase I trial began in 2017 to evaluate the safety of the ring over 84 days. The trial was not completed.
Additional Information
References: Press release: http://www.sciencedaily.com/releases/2013/09/130927123509.htm
Clinicaltrials.gov Identified NCT02006264
Clinicaltrials.gov Identified NCT02762617
Press release: http://www.sciencedaily.com/releases/2013/09/130927123509.htm
Clinicaltrials.gov Identified NCT02006264
Clinicaltrials.gov Identified NCT02762617